TWiV 811: COVID-19 clinical update #82 with Dr. Daniel Griffin

In COVID-19 clinical update #82, Daniel Griffin reviews vaccines for 5-12 years old, safety of a third vaccine dose, Oklahoma reinfection data, Regencov outcomes, Pfizer protease inhibitor, impact of Tocilizumab, and incidence of long COVID. Hosts: Daniel Griffin and Vincent Racaniello Subscribe (free): iTunes , Google Podcasts , RSS , email Become a patron of TWiV! Links for this episode Data on Pfizer-BioNTech in 5-12 year olds (Pfizer) Safety of additional vaccine dose (MMWR) Oklahoma reinfection rates (OK DOH) Regencov outcomes (NEJM) Pfizer protease inhibitor trial (Pfizer) WHO recommends antibody therapy (Hosp Health) Tocilizumab use in hospitalized patients (Resp Care) Long COVID (PLoS Medicine) Letters read on TWiV 811 Timestamps by Jolene . Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]